Martin Blogg

3.2k total citations · 1 hit paper
36 papers, 2.5k citations indexed

About

Martin Blogg is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Martin Blogg has authored 36 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Physiology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Immunology and Allergy. Recurrent topics in Martin Blogg's work include Asthma and respiratory diseases (27 papers), Allergic Rhinitis and Sensitization (14 papers) and Respiratory and Cough-Related Research (12 papers). Martin Blogg is often cited by papers focused on Asthma and respiratory diseases (27 papers), Allergic Rhinitis and Sensitization (14 papers) and Respiratory and Cough-Related Research (12 papers). Martin Blogg collaborates with scholars based in United Kingdom, United States and Switzerland. Martin Blogg's co-authors include Jean Bousquet, S. Hedgecock, Marc Humbert, Helen Fox, K. Surrey, Jon G. Ayres, Raymond G. Slavin, G. Ayre, Jean‐Louis Hébert and H. Fox and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and BJOG An International Journal of Obstetrics & Gynaecology.

In The Last Decade

Martin Blogg

32 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

2004 839 citations Marc Humbert, Richard Beasley et al. Allergy profile →

Peers

Martin Blogg

PHYSI

PRM

IMMUN

RHEUM

J. Thirlwell United Kingdom

Sandhia Ponnarambil United States

May Mo United States

Patricia Rohane United States

Julie Olsson United States

JingYuan Feng United States

Necdet B. Gunsoy United Kingdom

Katerina Samara Greece

A. Prudhomme France

William Kelly United States

J. Thirlwell United Kingdom

Martin Blogg

1.7k ×0.8

PHYSI

1.3k ×0.7

PRM

1.0k ×0.7

243 ×0.9

IMMUN

85 ×0.5

RHEUM

Citations per year, relative to Martin Blogg Martin Blogg (= 1×) peers J. Thirlwell

Countries citing papers authored by Martin Blogg

Since Specialization

Citations

This map shows the geographic impact of Martin Blogg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Blogg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Blogg more than expected).

Fields of papers citing papers by Martin Blogg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Blogg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Blogg. The network helps show where Martin Blogg may publish in the future.

Co-authorship network of co-authors of Martin Blogg

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Blogg. A scholar is included among the top collaborators of Martin Blogg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Blogg. Martin Blogg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arıcı, Mustafa, et al.. (2025). Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye. International Journal of Nephrology and Renovascular Disease. Volume 18. 27–42.

Blogg, Martin, et al.. (2025). Treating moderate to severe menopausal vasomotor symptoms with fezolinetant: responder analysis of the phase 3b DAYLIGHT study. Menopause The Journal of The North American Menopause Society. 32(6). 488–498.

Santoro, Nanette, et al.. (2025). Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Current Medical Research and Opinion. 41(2). 375–384.

Cano, Antonio, Rossella E. Nappi, Nanette Santoro, et al.. (2024). Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG An International Journal of Obstetrics & Gynaecology. 131(9). 1296–1305. 9 indexed citations

Fliser, Danilo, et al.. (2023). Real-Life Anemia Management Among Patients with Non-Dialysis-Dependent Chronic Kidney Disease in Three European Countries. International Journal of Nephrology and Renovascular Disease. Volume 16. 115–129.

Somerville, Laura L., et al.. (2013). Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Current Medical Research and Opinion. 30(1). 59–66. 15 indexed citations

Busse, William W., Roland Buhl, Carlos Fernández Vidaurre, et al.. (2012). Omalizumab and the risk of malignancy: Results from a pooled analysis. Journal of Allergy and Clinical Immunology. 129(4). 983–989.e6. 125 indexed citations

Kulus, Marek, et al.. (2010). Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Current Medical Research and Opinion. 26(6). 1285–1293. 70 indexed citations

Wahn, Ulrich, Cristina Martín, P. R. Freeman, Martin Blogg, & Pablo A. Jimenez. (2009). Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 64(12). 1780–1787. 58 indexed citations

10.

Slavin, Raymond G., et al.. (2009). Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. Journal of Allergy and Clinical Immunology. 123(1). 107–113.e3. 104 indexed citations

11.

Niven, Robert, Kian Fan Chung, Zoya Panahloo, Martin Blogg, & G. Ayre. (2008). Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. Respiratory Medicine. 102(10). 1371–1378. 69 indexed citations

12.

Humbert, Marc, L. P. Boulet, Robert Niven, et al.. (2008). Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy. 64(1). 81–84. 41 indexed citations

13.

Bousquet, Jean, Klaus F. Rabe, Marc Humbert, et al.. (2007). Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respiratory Medicine. 101(7). 1483–1492. 231 indexed citations

14.

Berger, William, Nancy K. Ostrom, M. Solèr, et al.. (2005). Omalizumab significantly reduces asthma exacerbations in patients with severe persistent asthma: A pooled analysis. Journal of Allergy and Clinical Immunology. 115(2). S75–S75. 2 indexed citations

15.

Meltzer, Eli O., et al.. (2005). Omalizumab, an anti-IgE antibody, significantly reduces emergency visits in patients with severe persistent asthma: A pooled analysis. Journal of Allergy and Clinical Immunology. 115(2). S76–S76. 1 indexed citations

16.

Humbert, Marc, Richard Beasley, Jon G. Ayres, et al.. (2004). Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 60(3). 309–316. 839 indexed citations breakdown →

17.

Vignola, A M, Marc Humbert, Jean Bousquet, et al.. (2004). Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 59(7). 709–717. 309 indexed citations

18.

Ayres, Jon G., Bernard Higgins, Edwin R. Chilvers, et al.. (2004). Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma. Allergy. 59(7). 701–708. 225 indexed citations

19.

Bousquet, Jean, Pedro Cabrera, Neville Berkman, et al.. (2004). The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 60(3). 302–308. 312 indexed citations

20.

Ayres, Jon G., Robert Niven, G. Ayre, Martin Blogg, & Helen Fox. (2003). Omalizumab reduces the rate of asthma deterioration-related incidents in patients with poorly controlled allergic asthma. Journal of Allergy and Clinical Immunology. 111(2). S202–S202. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact